(CIDRAP News) – A year-long voluntary moratorium on research involving transmissible H5N1 avian flu viruses ended today with a letter from a group of scientists that supports resuming the work in countries that have addressed the biosafety issues involved.
(CIDRAP News) – Novartis's new cell-culture based influenza vaccine factory in North Carolina has begun making a prepandemic H5N1 flu vaccine and is ready to start producing vaccines for a real pandemic when needed, the company and federal health officials announced yesterday.
The facility in Holly Springs, N.C., billed as the first of its kind in the United States, was dedicated yesterday after a long testing process.
(CIDRAP News) – The era of cell-based influenza vaccine production in the United States seemed to move closer today as Novartis unveiled its new, nearly billion-dollar manufacturing plant in Holly Springs, N.C., but onshore production and marketing of cell-based vaccines remains a few years away.
(CIDRAP News) Questions about the tardy US supply of pandemic H1N1 vaccine have increased with the report that most of Novartis's doses may not reach the country until early in 2010 and a European regulatory recommendation that may have implications for the global vaccine supply.